Exthera Medical Corporation

Medicarb Ab

Astra Aktiebolag

Norsk Hydro, A.s.

Exthera Ab

Olle Larm

Robert S Ward

Lars Adolfsson

Keith R McCrea

Tomas Bergstrom

Ibrahim Gouda

Marcus Back

Tomas Bergström

Hans-Arne Hansson

Jonas Axelsson

Gunilla Johansson-Rudén

Gunilla Johansson-Rud&eacute;n

Andrzej Werynski

Elisabeth Scholander

Rolf Seljelid

Anders Westermark

Tomas Bergstr&ouml;m

Keith McCrae

Andrzej Jozwiak

Keith McCREA

Keith Mccrea

Thomas BERGSTRÖM

Thomas Bergström

The method is described as the removal of mediators that contribute to the pathogenesis of cancer from blood by contacting the blood with a solid, essentially non-micro-porous substrate which has been surface treated with heparin, heparan sulfate and, optionally, other molecules or chemical groups (the adsorbent media or media) having a binding affinity to the mediator, and wherein the size of the interstitial channels within said substrate are balanced with the amount of interstitial substrate surface area such that high flow rates of blood past said substrate creates a flow transport that is characterized by convection transport more than Brownian diffusion transport.

Use of heparin and carbohydrates to treat cancer

The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non microporous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.

Methods for removing cytokines from blood with surface immobilized polysaccharides

The present invention relates to a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood/use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of said pathogenic microbe, inflammatory cell or inflammatory protein from mammalian blood/use of a carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, wherein said carbohydrate is immobilized on a solid substrate, in the preparation of a device for treatment of a condition caused or aggravated by said pathogenic microbe, inflammatory cell or inflammatory protein and a method for treatment of a mammalian subject suffering from a condition caused or aggravated by a pathogenic microbe, an inflammatory cell or an inflammatory protein.

Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood

A blood filtration method, system, device and media for removing gram negative bacteria from the blood wherein the media includes a substrate coated with mannose optionally in constitution with substrate coated with heparin.

Blood filtration system containing mannose coated substrate

Method for extracorporeal removal of pathogenic microbe, an inflammatory cell or an inflammatory protein from blood

The present invention relates to a device for extracorporeal removal of harmful agents from blood or blood com-Components, comprising full length heparin immobilized on a solid substrate by covalent end point attachment. The present invention also relates to a method for extracorporeal removal of a harmful agent from mammalian blood or blood components. The present invention further relates to a process for covalent end point attachment of full length heparin to a solid substrate.

Device and method for restoration of the condition of blood

The present invention relates to a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood/use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of said pathogenic microbe, inflammatory cell or inflammatory protein from mammalian blood/use of a carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, wherein said carbohydrate is immobilized on a solid substrate, in the preparation of a device for treatment of a condition caused or aggravated by said pathogenic microbe, inflammatory cell or inflammatory protein/and a method for treatment of a mammalian subject suffering from a condition caused or aggravated by a pathogenic microbe, an inflammatory cell or an inflammatory protein.

A composition having an ionic complex of chitosan and a negatively charged polysaccharide, selected from the group consisting of heparin, heparan sulfate and dextran sulfate, for use in the treatment of mucositis in a mammalian subject, to a method of preventing or treating mucositis in a mammalian subject, by applying topically a composition having an ionic complex of chitosan and a negatively charged polysaccharide, selected from the group consisting of heparin, heparan sulfate and dextran sulfate. The composition further relates to a pharmaceutical composition for topical administration of an ionic complex of chitosan and heparin.

Treatment of oral mucositis by administering an ionic complex of chitosan and a negatively charged polysaccharide selected from heparin, heparan sulfate and dextran sulfate

The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non micro-porous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.

Method for removing cytokines from blood with surface immobilized polysaccharides

The present invention relates to a device for extracorporeal removal of harmful agents from blood or blood components, comprising full length heparin immobilized on a solid substrate by covalent end point attachment. The present invention also relates to a method for extracorporeal removal of a harmful agent from mammalian blood or blood components. The present invention further relates to a process for covalent end point attachment of full length heparin to a solid substrate.

A method of preparing conjugates by means of covalent coupling of a polysaccharide selected from heparin, heparin derivatives, at least partially deacerylated dermatan sulphate and dextran sulphate and a solid substance containing primary amino groups, said method comprising the following steps: a) reduction of the saccharide so that its terminal monosaccharide unit is converted to an alditol; b) periodate oxidation of the alditol formed in step a) to the formation of a terminal aldehyde group under cleavage of the monosaccharide unit between two vicinal groups selected from hydroxyl and amino groups; and c) reductive coupling of the alditol via the aldehyde group to the amino group of the solid substrate.

Growing community of inventors

Bromma, Sweden

Olle Larm